Vitoria Barbosa Paes, Leonardo da Silva Lara, Lorraine Martins Rocha Orlando, Guilherme Curty Lechuga, Thamyris Pérez de Souza, Byanca Silva Ferreira, Mariana de Oliveira Zago, Maurício Silva Dos Santos, Mirian Claudia de Souza Pereira
{"title":"Insights into the Antiparasitic Activity of Pyrazole-benzimidazole against Trypanosoma cruzi.","authors":"Vitoria Barbosa Paes, Leonardo da Silva Lara, Lorraine Martins Rocha Orlando, Guilherme Curty Lechuga, Thamyris Pérez de Souza, Byanca Silva Ferreira, Mariana de Oliveira Zago, Maurício Silva Dos Santos, Mirian Claudia de Souza Pereira","doi":"10.2174/0109298673342932241016032905","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chagas disease (CD), a life-threatening disease caused by Trypanosoma cruzi, remains a significant global public health concern. The limited efficacy of the available drugs (nifurtimox and benznidazole), their severe adverse events, and the unsatisfactory outcomes of clinical trials drive the search for new, effective, and safe drugs.</p><p><strong>Objective: </strong>This study describes the synthesis, structural characterization, and in vitro antiparasitic activity of novel pyrazole-benzimidazole derivatives against mammalian developmental stages of T. cruzi.</p><p><strong>Methods: </strong>Phenotypic screening was used to assess the effect of pyrazole-benzimidazole derivatives against T. cruzi. Three-dimensional cardiac spheroids were employed to evaluate the toxic effect and drug efficacy. Molecular docking and cysteine protease activity were also performed.</p><p><strong>Results: </strong>Pyrazole-benzimidazole derivatives showed activity against both trypomastigotes and intracellular amastigotes. Compounds 1i (IC50 = 6.6 μM) and 1j (IC50 = 9.4 μM) demonstrated the most potent activity with a high selectivity index (SI > 45) against intracellular amastigotes. Both compounds exhibited high efficacy on 3D cardiac spheroids, effectively reducing the parasite load by over 80%. Molecular docking analysis revealed that both compounds target the catalytic domain of cruzain through pi-stacking and hydrogen bonding interactions and inhibit T. cruzi cysteine protease. These derivatives also showed an additive effect in combination with the reference drug (Bz).</p><p><strong>Conclusion: </strong>Our findings emphasize the significance of pyrazole-benzimidazole hybrids in the search for new anti-T. cruzi agents.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673342932241016032905","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chagas disease (CD), a life-threatening disease caused by Trypanosoma cruzi, remains a significant global public health concern. The limited efficacy of the available drugs (nifurtimox and benznidazole), their severe adverse events, and the unsatisfactory outcomes of clinical trials drive the search for new, effective, and safe drugs.
Objective: This study describes the synthesis, structural characterization, and in vitro antiparasitic activity of novel pyrazole-benzimidazole derivatives against mammalian developmental stages of T. cruzi.
Methods: Phenotypic screening was used to assess the effect of pyrazole-benzimidazole derivatives against T. cruzi. Three-dimensional cardiac spheroids were employed to evaluate the toxic effect and drug efficacy. Molecular docking and cysteine protease activity were also performed.
Results: Pyrazole-benzimidazole derivatives showed activity against both trypomastigotes and intracellular amastigotes. Compounds 1i (IC50 = 6.6 μM) and 1j (IC50 = 9.4 μM) demonstrated the most potent activity with a high selectivity index (SI > 45) against intracellular amastigotes. Both compounds exhibited high efficacy on 3D cardiac spheroids, effectively reducing the parasite load by over 80%. Molecular docking analysis revealed that both compounds target the catalytic domain of cruzain through pi-stacking and hydrogen bonding interactions and inhibit T. cruzi cysteine protease. These derivatives also showed an additive effect in combination with the reference drug (Bz).
Conclusion: Our findings emphasize the significance of pyrazole-benzimidazole hybrids in the search for new anti-T. cruzi agents.
期刊介绍：
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
